
Attorney's analysis: 'fugitive emissions' heighten Goodyear cancer risk
An analysis conducted by an attorney who formerly represented plant workers suggests emissions of a known chemical carcinogen from the Goodyear Tire and Rubber Co. facility in Niagara Falls may be much worse than state regulators have previously suggested.
The analysis by attorney Steve Wodka, as first reported by the Buffalo News on Sunday, takes into account so-called 'fugitive emissions,' which include leaks and other points of exit that result in the organic chemical ortho-toluidine escaping from the site while bypassing smokestacks.
Wodka's analysis, which relied on data Goodyear provided to the state and the federal Environmental Protection Agency, suggests total pollution, including chemicals released from smokestacks and fugitive emissions, could be 400 times higher than the state's acceptable limits.
Wodka outlined his findings while expressing serious concerns about the potential impact of the chemical's release on the surrounding neighborhood in an April 8 letter sent to Julie Barrett O'Neil, regional director of the New York State Department of Environmental Conservation.
'The State of New York has a moral obligation, if not a legal duty, to inform the hundreds of families that live within the areas impacted by the real world current combination of both stack and fugitive emissions, and the parents of the children who attend the Cataract Elementary School, that their health is at risk from the emissions from the nearby Goodyear plant,' Wodka wrote to O'Neil.
Studies have shown O-T contributed to cases of bladder cancer among the workers at the Goodyear plant in the Falls. Emissions standards for the chemical's release in New York are supposed to follow the state's Annual Guideline Concentration, which is .02 micrograms per cubic meter.
Last September, WBFO, in collaboration with Public Health Watch and Inside Climate News, first reported that the plant, located off 56th Street in the LaSalle section of the city, has been emitting ortho-toluidine and another pollutant, diphenylamine, known as DPA, at levels 1,000% higher than what state regulators deem safe.
WBFO and its reporting partners cited a July 2023 notice of violation issued to Goodyear by the DEC that informed the company of its failure to control the emissions. The notice focused on two pollution-control devices that failed to properly control the emission of the pollutants. The news outlet reported estimates that the site has been releasing pollutants at higher levels than allowed by the state for at least 15 years.
Earlier this year, the DEC entered into a consent order with Goodyear in which the company agreed to install temporary pollution control measures to reduce stack emissions by April 10. Under the order, Goodyear is required to have permanent pollution controls installed by Oct. 31, 2026.
The DEC and Goodyear continue to insist emissions from the plant pose 'no imminent public health risk to the community.'
'At Goodyear, the health and safety of our associates and the communities in which we work is our top priority,' Goodyear said in a statement released by a spokesperson. 'The DEC and New York State health authorities have publicly stated that historical emission limits are 'currently protective of the surrounding community's air quality' and 'there is no risk to the community' based on their modeling.'
In his letter to O'Neil, Wodka pointed to modeling done as part of Goodyear's 2018 air permit application and its proposed 2023 protocol for plant operations. He noted that the company identified 13 emissions sources, which he described as stacks, that were emitting O-T into the air from the Falls plant. He also noted last year's DEC modeling that showed the extent of the plume from the 13 sources. He said neither Goodyear nor the DEC has ever modeled or even proposed to model the 'real-world combination' of both the 13 O-T emission sources and the plant's fugitive emissions.
In his letter, Wodka noted that the most recent data available from the EPA's toxic release inventory indicated that Goodyear reported in 2023 emissions totaling 1,344 pounds of O-T into the air in the Falls. Of that, he said, 133 pounds, or 10% resulted from stack emissions, with the remainder, 1,211 pounds, or 90%, representing fugitive emissions.
A plume map generated by the DEC showed the extent of the cloud of emissions coming from the plant and its impact on the surrounding neighborhood.
When fugitive emissions are added to develop a similar air dispersion model, Wodka said the results show a wider area of impact that extends as far as '71st Street and Niagara Falls Boulevard, to Buffalo Avenue on the south, west more than a mile past the intersection of Packard Road and Hyde Park Boulevard, and to the north beyond Niagara Falls Boulevard.'
Wodka described Cataract Elementary School, located on Girard Avenue, as being 'well within' the plume that is above the state safety limit of .02 micrograms per cubic meter.
'After more than 35 years of studies and testing, the workers in the plant know, or should know, of the risk to their health from their exposure at the plant. However, the residents have never been told,' Wodka wrote.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
a day ago
- Yahoo
Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics
Ra'anana, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the 'Company' or 'Polyrizon'), a biotechnology company developing intranasal drug delivery systems, today announced encouraging preclinical results from a recent study evaluating its proprietary hydrogel-based Trap & Target (T&T) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated that Polyrizon's hydrogel formulation achieves targeted deposition in the upper regions of the nasal cavity—critical for central nervous system (CNS) drug delivery. The promising results are part of a collaborative study between the Company and the Department of Food and Drug of the University of Parma (Italy), led and conducted by Professor Fabio Sonvico, a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company's Scientific Advisory Board. Using a silicone-based human nasal cast and fluorescein-traced imaging, the Polyrizon hydrogel formulation was shown to exhibit a preferential accumulation of over 60% in the middle and upper turbinates, the region's most favorable for nose-to-brain transport. This region-specific delivery has the potential to be particularly promising for CNS indications, such as opioid overdose (e.g., naloxone) and benzodiazepine for epileptic seizures, where rapid and direct access to the brain can be lifesaving. 'The results validate the unique capabilities of our T&T technology in achieving localized deposition in anatomically favorable zones of the nasal cavity,' said Tomer Izraeli, CEO at Polyrizon. 'We believe that this has the potential to open a strategic path forward for leveraging our intranasal platform in the development of therapies for acute neurological and psychiatric conditions.' Polyrizon's hydrogel demonstrated consistent, concentrated delivery to the upper nasal segments while maintaining favorable handling characteristics. These findings support the continued preclinical development of the T&T platform for CNS-targeted applications. Polyrizon intends to further validate these results in animal models and initiate safety studies as part of its translational roadmap for the T&T technology. About Polyrizon Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon's proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a 'biological mask' with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit Forward Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its belief that its Trap and Target™ (T&T) platform has the potential to opens a strategic path forward for leveraging its intranasal platform in the development of therapies for acute neurological and psychiatric conditions, the continued preclinical development of the T&T platform for CNS-targeted applications and its intention to further validate these results in animal models and initiate safety studies as part of its translational roadmap for the T&T technology. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ('SEC'), including, but not limited to, the risks detailed in the Company's annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites. Contacts: Michal Efraty Investor Relations IR@


Bloomberg
2 days ago
- Bloomberg
Astra's Early Test Fuels Hope for Cell Therapy Approach to Lupus
AstraZeneca Plc said a handful of patients with lupus went into remission after getting an experimental treatment, as the UK drugmaker plows billions into the growing area of cell therapy called CAR-T. The medicine, which Astra gained in the takeover of Gracell Biopharmaceuticals Inc., has only just entered clinical trials. But the tiny study, conducted in Shanghai, had a stark impact on ten young volunteers whose disease wasn't controlled by earlier treatment. Six of them no longer showed signs of having lupus nine months after the one-time infusion, according to early results.
Yahoo
4 days ago
- Yahoo
The most depressing jobs in the country revealed in new study
Job seekers may want to consider the toll that specific careers can have on their mental health. A huge new study published on Friday examined the relationship between careers and depression rates. The study analyzed survey data from 536,279 workers across 37 states from 2015 to 2019. Out of half a million U.S. workers, 80,319 of them admitted to being diagnosed with depression at some point during their lives, with women being diagnosed twice as often as men. Separating the results by industry, the study saw that people who worked in community and social services had the highest rate of lifelong diagnosed depression at 20.5 percent. The second highest on the list was food prep and serving jobs at 20.1 percent. Other industries with high lifetime diagnosed depression rates are: arts, entertainment, sports, and media at 18.6 percent; accommodation and food services at 18.4 percent; health and social assistance at 18.2 percent; retail trade at 17.7 percent; and legal, education, and library jobs tied at 16.1 percent. Industries with lower lifetime diagnosed depression rates included mining jobs at 6.7 percent, construction at 8.9 percent, and agriculture and engineering jobs at nine percent. Although mining and construction may have lower depression rates, those industries also have the highest suicide rates among U.S. workers. The researchers suggest that the gap may be explained because blue-collar men are less likely to seek mental services due to a preexisting stigma or limited access in rural areas. Despite the results of the study, there are some jobs out there that are almost stress-free and also come with a large paycheck. Back in December 2024, Resume Genius released its list of the highest-paying jobs that also reported low levels of stress. Their study described 'low-stress jobs' as ones that typically require fewer demands, more predictable work hours, supportive environments, and manageable workloads. All of the jobs on the list required the person to have at least a Bachelor's degree. The list was compiled using data from the U.S. Bureau of Labor Statistics (BLS) and the career site O*NET Online. The high-stress jobs were filtered out using O*NET and then cross-referenced against the BLS's Occupational Outlook Handbook, with the national median salary set at $48,060 and viewing jobs that showed 'faster-than-average growth.' The best jobs included: water source specialist, astronomer, actuary, environmental economist, mathematician, and geographer.